Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00984477 | Study to Investigate the Activity of AZD5122 When Given as a Single Dose to Healthy Male Subjects | PHASE1 | COMPLETED | 100 | — | — | Sep 1, 2009 | Nov 1, 2009 | Dec 4, 2009 | 1 | United Kingdom |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | AZD5122 oral suspension (part A and B) |
| 2 | PLACEBO_COMPARATOR | Placebo oral suspension (part A) |
| 3 | EXPERIMENTAL | AZD5122 oral and IV infusion (part B) |
| Name | Type | Description |
|---|---|---|
| AZD5122 | DRUG | A single dose of oral suspension |
| Placebo | DRUG | A single dose of oral suspension |
Inclusion Criteria: * Provision of signed and dated, written informed consent. * Normal physical examination, laboratory values, blood pressure and pulse * Healthy male caucasian subjects Exclusion Criteria: * Subjects must not have any history of gastrointestinal, hepatic or renal disease, or an...